GlassScriptPhysician profile
Issam D Moussa
NPI 1407933302
$87,621.59
in general payments reported to CMS, 2019-2025
24 companies · $6,880 in 2025
The $6,880 reported for 2025 was more than what 86% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $15K · 2021: $13K · 2022: $18K · 2023: $9,512 · 2024: $3,900 · 2025: $6,880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,954 · Consulting Fee: $5,625 · Travel and Lodging: $4,713 · Honoraria: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,953.68 |
| Consulting Fee | $5,625.00 |
| Travel and Lodging | $4,713.07 |
| Honoraria | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $39,475.52 | 2019-2021 | |
| Abbott Laboratories | $21,078.35 | 2019-2025 | Optis, Coroflow, Pressurewire |
| Medtronic, INC. | $10,644.53 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Onyx Frontier |
| Canon Medical Systems USA, INC. | $5,548.24 | 2023-2025 | Interventional Angiography System, Ct Scanner |
| Edwards Lifesciences Corporation | $3,034.67 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $2,802.94 | 2019-2025 | Watchman Access System, Avvigo Guidance System, Varithena Administration Pack |
| Philips North America LLC | $2,086.29 | 2023-2024 | (Bs3) Intracardiac Und, (9520) Igt Devices Und, (Ao0) Igt Devices Intracardiac |
| Heartflow, INC. | $562.97 | 2023 | Ffrct |
| Cathworks, INC. | $302.38 | 2025 | Ffrangio |
| Siemens Medical Solutions USA, INC. | $273.90 | 2019-2024 | Acuson Sc2000 Diagnostic Ultrasound System |
| Biosense Webster, INC. | $271.74 | 2025 | Nuvision Ice Catheter |
| Penumbra, INC. | $250.99 | 2022-2023 | Indigo System |
| Celonova Biosciences, INC. | $221.95 | 2019-2020 | |
| Cook Medical LLC | $214.80 | 2019 | |
| Abiomed | $157.91 | 2021-2023 | Impella |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $126.52 | 2024-2025 | Savvywire, Cardiva Vascade Mvp Vvcs 6-12f |
| Janssen Scientific Affairs, LLC | $119.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $114.41 | 2025 | |
| Shockwave Medical, INC | $82.92 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| W. L. Gore & Associates, INC. | $76.75 | 2019 | |
| Teleflex LLC | $43.17 | 2022-2023 | Guideliner |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.50 | 2023 | Lifevest |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Issam Moussa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.